Abstract Irbesartan,(2-butyl-3-({4-[2-(2H-1, 2, 3, 4-tetrazol-5-yl) phenyl] phenyl} methyl)-1, 3-
diazaspiro [4.4] non-1-en-4-one), is a member of non-peptide angiotensin II receptor …

Irbesartan (IRB), an angiotensin II receptor AT1 blocker, is an antihypertensive agent
commonly used with Sitagliptin (STG), a novel antidiabetic agent in diabetes. A finalised and …

As the world's population ages, the prevalence of age‐related neurological disorders such
as Alzheimer's disease (AD) is increasing. There is currently no treatment for Alzheimer's …

The combined therapy benefits of losartan and rosuvastatin, within the vascular injury, have
been well characterized. Nonetheless, the pharmacokinetic interactions between such …

End-stage renal disease (ESRD) is the last stage of chronic kidney disease, characterized
by the progressive accumulation of uremic toxins (UTs). Hemodialysis is the standard …

Aim & Objective: This study evaluates the potential of combining paclitaxel (PTX) and
bortezomib (BTZ) for breast cancer therapy. Materials & Methods: The nanoformulation was …

The linagliptin (LIN) and pioglitazone HCl (PIO) combination, currently undergoing phase III
clinical trials for diabetes mellitus treatment, demonstrated significant improvements in …

Despite the prevalent utilization of antidepressant combinations in clinical settings, concerns
persist regarding heightened side effects and potential drug–drug interactions (DDI). In …

A sensitive, reproducible, and specific liquid chromatography tandem mass spectrometry
method was developed and validated to simultaneously determine the concentration of …

Sartans, as a class of antihypertensive drugs, pose a threat to human health when illegally
added to herbal beverages. It is crucial to detect sartans in herbal beverages. We have …